India approves its first dengue vaccine Qdenga: How it works, who is eligible, and why it isn't a silver bullet

Qdenga's approval is a symptom of India's and Japan's competing narratives on innovation and medical progress, masking deeper power dynamics at play.

The differing framing of the vaccine as 'India's breakthrough' or 'Japan's medical innovation' reveals a power imbalance between the two nations. The lack of transparency around funding and potential side effects further obscures the true cost of this 'medical breakthrough'.

This is our editorial interpretation of the cross-source evidence above, not a report of established fact. The sourced coverage it draws on is listed below.